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Almost 90 years have passed since Alexander Fleming
discovered the antimicrobial activity of lysozyme, the
first natural antibiotic isolated from our body. Since
then, various types of molecules with antibiotic
activity have been isolated from animals, insects,
plants, and bacteria, and their use has revolutionized
clinical medicine. So far, more than 1,200 types of
peptides with antimicrobial activity have been isolated
from various cells and tissues, and it appears that all
living organisms use these antimicrobial peptides
(AMPs) in their host defense. In the past decade,
innate AMPs produced by mammals have been shown
to be essential for the protection of skin and other
organs. Their importance is because of their pleio-
trophic functions to not only kill microbes but also
control host physiological functions such as inflam-
mation, angiogenesis, and wound healing. Recent
advances in our understanding of the function of
AMPs have associated their altered production with
various human diseases such as psoriasis, atopic
dermatitis, and rosacea. In this review, we summarize
the history of AMP biology and provide an overview
of recent research progress in this field.
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AMPS: A DIVERSE GROUP OF MOLECULES
The antimicrobial peptides (AMPs) have redefined the way
we think about immune defense and human disease.
Unfortunately, this name is misleading, as the term ‘‘anti-
microbial’’ describes more about their history of discovery
than the potent influence these molecules have on cell
behavior. As such, alternative terms for AMPs have also
appeared. These include better descriptive terms such as
‘‘host defense peptides,’’ ‘‘alarmins,’’ and even ‘‘defensins’’
(used in a broad context instead of the gene family).
However, to appreciate the history of the discovery of these
molecules, as well as their common unifying function to kill
microbes, the term AMPs will be used in this review.
Over the past two decades, more than 1,200 AMPs have
been identified or predicted from various organisms. For a
partial list of these, see the Antimicrobial Peptide Database
(http://aps.unmc.edu/AP/main.php). AMPs in general consist
of 10–50 amino-acid residues. These peptides lack any
specific consensus amino-acid sequences that are associated
with biological activity, but most of them maintain certain
common features, such as containing positive charge and
relatively hydrophobic and amphipathic structure. On the
basis of their amino-acid composition, size, and conforma-
tional structures, AMPs can be divided into several cate-
gories, such as peptides with a-helix structures, peptides with
b-sheet structures stabilized by disulfide bridges, or peptides
with extended or loop structures, as reviewed in Lai and
Gallo (2009). Classic AMPs, such as LL-37 and human
b-defensins (hBDs), are amphipathic molecules that possess
clusters of positively charged and hydrophobic charged
amino-acid chains. This amphipathic feature is thought to
allow them to interact with negatively charged phospholipid
head groups and hydrophobic fatty acid chains of microbial
membranes, resulting in pore formation on the microbial
membrane and release of cytosol components (Glaser et al.,
2005; Wimley, 2010). It is the membrane-active nature of the
AMPs that likely controls their function, but as we continue to
study these molecules we learn that their function is much
more than originally expected.
AMPS: THE HOT NEW TOPIC PRECEDED BY 90 YEARS OF
DISCOVERY
Many immunologists consider the study of AMPs as a
relatively new topic that led the way toward recognition of
our modern understanding of innate immunity. AMPs are a
primary effector system that functions with the detection
system generated by microbial pattern recognition genes such
as the Toll-like receptors (TLRs). However, the process of the
discovery of innate antimicrobials goes back much further in
history. Alexander Fleming first recognized the presence of
a soluble antimicrobial substance produced by humans
B90 years ago. Fleming observed the bactericidal and bacte-
riostatic activities of nasal secretions from a patient suffering
from acute coryza when he treated bacterial culture plates
with this material (Fleming, 1922). He named the activity
lysozyme because of its capacity to ‘‘lyse’’ bacterial lawns on
a dish. Subsequently, he found lysozyme activity in various
human physiological fluids and tissues of animals, as well as
egg whites. Such observations indicated to him that lysozyme
performed a wide range of functions as a part of our immune
system. In 1928, Fleming subsequently discovered that
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penicillin extracted from the culture of green mold, Peni-
cillium notatum, stopped the growth of various bacteria
(Fleming, 1929). In the 1940s, Howard Florey and Ernst
Chain brought penicillin’s potential for medical use to
fruition. They shared the 1945 Nobel Prize for Medicine
along with Fleming for the discovery of penicillin and its
therapeutic effects. Approximately 40 years after Fleming’s
lysozyme discovery, the primary structure of egg white
lysozyme was characterized (Canfield, 1963), but by this
point the interest in natural host antibiotics had decreased
and the importance of this immune defense strategy was all
but forgotten.
Antibiotics were also recognized in prokaryotic cells at an
early stage in modern medicine. In 1939, Rene´ Dubos
isolated antimicrobial substances, named gramicidin, from
culture supernatant of soil bacteria, Bacillus brevis. Grami-
cidin exhibited bactericidal or bacteriostatic activity against a
wide range of Gram-positive bacteria in vitro and in vivo
(Dubos, 1939a, b). Gramicidin was later shown to be a
heterogeneous mixture of six AMPs that were identified as
N-formylated polypeptides with alternating L- and D-amino
acids (Sarges and Witkop, 1965a, b, c). In addition, applica-
tion of gramicidin on infected wounds on guinea-pig skin
rapidly disinfected pathogenic bacteria and successfully
suppressed infection, indicating the therapeutic potential of
gramicidin for clinical use (Gause and Brazhnicova, 1944).
To our knowledge, gramicidins were the first AMPs for which
the primary structures were characterized and the first
antibiotics to be commercially manufactured. This is avail-
able today as an over-the-counter antibiotic.
AMPs are now known to exist in all kingdoms. In contrast
to the large size of lysozymes, relatively small antimicrobial
molecules were observed to be induced in the hemolymph of
wax moth larvae after challenging with Pseudomonas
aeruginosa (Stephens and Marshall, 1962). Remarkably,
normal larvae that had received hemolymph from patho-
gen-challenged larvae exhibited passive protection against
bacterial infection, thus proving that these innate protective
molecules were soluble. In 1981, Hans Boman at the
Karolinska Institute pioneered the field of modern innate
immunity by seeking to identify the structure of innate insect
antimicrobial defense molecules. Initially, Steiner et al.
(1981) characterized primary structures of two AMPs, named
cecropins A and B, in hemolymph of the cecropia silk moth,
Hyalophora cecropia. Later, an AMP was isolated from small
intestines of a pig, which showed a high similarity with the
insect cecropins; therefore, it was named cecropin P1 (Lee
et al., 1989). However, the research group that discovered
the peptide later corrected their original conclusion and
discovered that this peptide in fact originated from the
parasite Ascaris nematodes (Andersson et al., 2003).
AMPs are also an integral part of the immune systems in
plants. In the early 1940s, Stuart and Harris (1942) demon-
strated that a crystalline protein isolated from wheat flour
exhibited antimicrobial effects against some human patho-
genic bacteria and yeast. It was a low-molecular-weight
proteinaceous material with high sulfur content and was
named purothionin (Balls et al., 1942). In the 1990s, a group
of small basic proteins was isolated from wheat endosperm
and characterized as purothionin homologs, and thus they
are called g-purothionins (Colilla et al., 1990). However,
subsequent study has established that purothionins and
g-purothionins are structurally unrelated (Bruix et al., 1993).
Considering that g-purothionins show a high structural
analogy with insect defensins, adapting b-sheets and single
a-helix structures stabilized by an eight-cysteine motif, they
are renamed as plant defensins (Broekaert et al., 1995; see
below for defensins). Transgenic plants overexpressing AMPs
have been explored for decades as a mechanism for disease
resistance. For example, expression of defensins in plants
confers enhanced resistance to phytopathogen attacks (Jha
et al., 2009; De Coninck et al., 2010).
The discoveries of defensins and cathelicidins led the way
for the emergence of our appreciation of AMPs in mammals.
Arginine-rich cationic peptides possessing potent antimicro-
bial activity against both Gram-positive and Gram-negative
bacteria were first identified in the lysosomal fraction of
guinea-pig polymorphonuclear leukocytes by mobility to the
cathode (Zeya and Spitznagel, 1963). Selsted et al. (1984,
1985) characterized primary structures of the six cationic
AMPs purified from rabbit neutrophils and named these
defensins (now classified as a-defensins). The research group
subsequently identified three defensins from normal human
neutrophils and also demonstrated that the peptides directly
inactivated herpes simplex virus (Ganz et al., 1985). These
defensins have a characteristic six-cysteine motif that forms
three intramolecular disulfide bonds (Cys1–Cys6, Cys2–Cys4,
and Cys3–Cys5). Selsted et al. (1993) isolated and character-
ized 13 AMPs with 38–42 amino-acid residues and the six-
cysteine motif of defensin in bovine granulocytes. However,
these defensin-like AMPs differed from a-defensins by
relatively longer amino-acid residues and different disulfide
pairings (Cys1–Cys5, Cys2–Cys4, and Cys3–Cys6); therefore,
they were newly classified as b-defensins. Genomic-based
approach have identified 28 human and 43 mouse b-defensin
genes (Schutte et al., 2002). Tang et al. (1999) characterized
an AMP in the leukocytes of rhesus monkey, which consisted
of 18 amino-acid residues with the six-cysteine motif of
defensin, and in which the peptide backbone is naturally
cyclized. This AMP was classified as y-defensin. Interestingly,
y-defensin mRNA transcripts are present in human bone
marrow, spleen, thymus, testis, and skeletal muscle, but a
premature stop codon aborts their translation (Nguyen et al.,
2003). In addition to the antibacterial activity, defensins also
offer effective antiviral and antifungal activities through
multiple modes of action. Mammalian defensins exhibit
strong viral-neutralizing activities by directly interacting with
viral envelope proteins (Hazrati et al., 2006; Doss et al.,
2009). In addition, a- and y-defensins directly interact with
specific viral receptors on the host cell, antagonizing viral
attachment, entry, or intracellular shuttling (Cole et al., 2002;
Furci et al., 2007). a-Defensins also kill Candida albicans by
lysing cells, possibly in a manner similar to their antibacterial
activity (Patterson-Delafield et al., 1980; Lehrer et al., 1985).
Zanetti et al. (1993) cloned a full-length complementary
DNA of Bac5, a proline-rich AMP that had previously been
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isolated from bovine neutrophils (Frank et al., 1990) from
myeloid bone marrow cell mRNA. The region upstream of
mature Bac5 peptide was found to share high homology with
cathelin (470% identity), an inhibitor of the cysteine
proteinase cathepsin L isolated from pig leukocytes (Kopitar
et al., 1989). Bovine or porcine leukocytes both contained at
least 10 structurally diverse AMPs composed of 12–100
amino-acid residues whose precursor proteins have cathelin-
like domains in the N-terminal; therefore, these AMPs were
named cathelicidins (Zanetti et al., 1995). Interestingly, the
number of different cathelicidins varies substantially among
species. In contrast to the multiplicity of cathelicidins in
bovine and porcine neutrophils, the human and murine
neutrophils express only a single cathelicidin gene (cathe-
licidin antimicrobial peptide (CAMP)) that encodes an
inactive precursor protein, hCAP18 in humans and CRAMP
in mouse (Agerberth et al., 1995; Cowland et al., 1995; Gallo
et al., 1997). Posttranscriptional processing cleaves out the
C-terminal cathelin domain from cathelicidin precursor
protein and makes the active AMP. For example, in humans,
active AMP composed of 37 amino acids beginning with two
leucines, named LL-37, is generated from hCAP18 (Zanetti,
2004). hCAP18 is cleaved extracellularly by proteinase 3 or
kallikrein family serine proteases to generate the active LL-37
peptides (Sorensen et al., 2001; Yamasaki et al., 2006). After
the cleavage, the N-terminal cathelin domain also exhibits
antimicrobial activity (Zaiou et al., 2003). The cathelicidin
AMPs generated from CAMP genes found between species
show little similarity to each other and are referred to as a
group solely because of the similarity of the precursor protein
that is predominated by the large cathelin domain. In
addition, they are remarkably variable in secondary struc-
tures. Many of them adopt an a-helical structure followed or
not by a hydrophobic unstructured tail (human LL-37, mouse
CRAMP, rabbit CAT-18), whereas others are proline/arginine
rich (bovine Bac-5 and porcine PR-39), tryptophan rich
(bovine indolicidin and porcine tritrpticin), and b-hairpin-like
structures (porcine protegrins) (Lehrer and Ganz, 2002;
Bulet et al., 2004). The cathelicidins have been cloned not
only in mammals, but also in fish (Chang et al., 2005; Maier
et al., 2008), chicken (van Dijk et al., 2005), snakes (Wang
et al., 2008; Zhao et al., 2008), and hagfish (Uzzell et al.,
2003).
AMPS IN THE SKIN: DEMONSTRATING RELEVANCE
As described above, in the early 1990s, AMPs were being
discovered in a wide range of organisms and cell types.
Despite this, we were surprised to discover that AMPs were
abundantly present in mammalian skin (Gallo et al., 1994).
These observations were first made in pig wounds with the
discovery of the porcine cathelicidin PR-39. Following this
discovery, Harder et al. (1997) described the production of
hBD-2 in human skin, lung, uterus, and trachea epithelia, and
elevated hBD-2 expression in human keratinocytes exposed
to pathogenic bacteria. Subsequent work from our group and
others demonstrated that AMPs are induced in the skin by
injury and are abundantly found in some inflammatory
processes such as psoriasis (Frohm et al., 1997; Dorschner
et al., 2001). The unique inflammatory environment of
psoriasis has been subsequently exploited for discovery of
multiple AMPs including a- and b-defensins, psoriasin, and
RNase7 (Harder and Schroder, 2005). A key advancement for
the field came with the capacity to not only purify and test
antimicrobial activity of isolated AMPs, but also to apply
modern mouse molecular genetic approaches to evaluation
of their function. These studies led the way to revise
perceptions of AMPs as evolutionarily ancient molecules
that have relatively insignificant roles in organisms that have
developed adaptive immune defense systems. The key initial
finding was that targeted deletion of cathelicidin proved that
this AMP was essential to the normal immune response and
resistance to bacterial skin infection (Nizet et al., 2001). This
critical role for cathelicidin has now been shown in many
tissues, mucosa, and body fluids, and for a wide range of
pathogenic bacteria, several viruses, and funguses, as well as
Leishmania (Gallo et al., 1997; Gordon et al., 2005; Gutner
et al., 2009; Doss et al., 2010; Kulkarni et al., 2011). Targeted
deletion of other molecules involved in pattern recognition
and processing of AMPs have shown similar results (Takeuchi
et al., 2000). Although similar in vivo data with defensins
have been more difficult to generate owing to the extensive
gene duplication of the a- and b-defensin gene families,
several reports have successfully demonstrated an important
role for defensins in host defense against bacteria and some
viruses in vivo. Metalloprotease-7-deficient mice, lacking
all mature a-defensins because of the loss of the protease
required for proteolytic cleavage, displayed a reduced
clearance of bacteria and higher mortality rates upon
pathogen challenge (Wilson et al., 1999). Mouse b-defen-
sin-1 knockout mice showed earlier weight loss and higher
mortality after influenza virus infection than wild-type mice
(Ryan et al., 2011). Conversely, transgenic overexpression
and knock-in of AMPs further supported these conclusions by
showing that the addition of excess AMPs can increase
resistance to some microbes (Salzman et al., 2003; Lee et al.,
2005).
At present, cathelicidins and b-defensins are the most
well-characterized AMPs found in the human skin (Lai and
Gallo, 2009; Wiesner and Vilcinskas, 2010). hBD-1 is
constitutively expressed in keratinocytes, but exhibits only
minor antibiotic killing activity in comparison with other
defensins (Zaalouk et al., 2004; Yadava et al., 2006). More
recently, the reduced form of hBD-1 has been shown to
become a potent antimicrobial peptide, of which reduction is
catalyzed by thioredoxin expressed in the epidermis (Schroe-
der et al., 2011). This suggests that the redox regulation is
crucial for the innate immune protection by hBD-1. The
expression levels of hBD-2, hBD-3, and human cathelicidin
in keratinocytes are very low at the steady state and typically
upregulated during infection, inflammation, and wounding
(Gallo et al., 2002; Froy, 2005). This suggests that with these
AMPs it is the secondary response of increasing expression
that serves to limit the severity of clinical symptoms when the
primary line of defense (constitutive expression of AMPs)
fails. Human keratinocytes also express many molecules that
were first discovered for reasons other than action as an
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AMP, but subsequently found to also inhibit microbial
growth. One example of these are the ribonucleotidases
(RNases). Of these, RNases 5 and 7 exhibit antimicrobial
activity against many pathogenic microorganisms indepen-
dent of the RNase activity (Huang et al., 2007; Abtin et al.,
2009; Zanger et al., 2009). The antimicrobial activity of these
RNases is inhibited by RNase inhibitor protein expressed in
epidermal keratinocytes, and, in turn, activated when the
RNase inhibitor is cleaved by stratum corneum serine
proteases (Abtin et al., 2009). An antimicrobial heterodimeric
complex, S100A8/S100A9 (calprotectin), is induced in
epidermal keratinocytes during Gram-negative bacteria
infection, and sensing of bacterial flagellin by TLR5 is critical
for the regulation of calprotectin (Abtin et al., 2010).
Cathelicidin, hBD-2 and -3, and antimicrobial histone H4
are detected in the cultured human sebocytes, and their
expression levels are upregulated in the presence of Gram-
positive bacteria or sebum-free fatty acids (Nagy et al., 2006;
Lee et al., 2009a; Nakatsuji et al., 2010). Large amounts of
psoriasin antimicrobial peptide accumulate in the epidermis
of sebaceous skin, as well as sebaceous glands, and are
secreted to the external skin surface (Glaser et al., 2005).
Sweat eccrine glands are also known as an important supplier
of AMPs to the epidermal surface. Dermcidin is an AMP
constitutively expressed as a small precursor protein in
eccrine sweat glands and secreted into sweat where active
AMPs are proteolytically generated (Schittek et al., 2001).
The skin provides a rapid first line of immune defense
against invading pathogens from outside environments by
constitutively and actively producing various AMPs. In
human skin, the main cellular sources of AMPs are
keratinocytes, mast cells, neutrophils, sebocytes, and eccrine
epithelial cells (Figure 1). This layered system of deployment
functions well because of the dual action of AMPs. First, as
we have thus far described, the secretion or release of these
peptides provides innate antibiotic-like action against in-
fectious pathogens. However, a key component of the overall
defense strategy of skin and other epithelial organs is that
alternate defense systems are activated to provide protection
in the event that microbes evade the first system. Clearly,
microbes are well adapted to develop antimicrobial resis-
tance, and many microbes are human pathogens because
they have succeeded in doing this. AMPs such as cathe-
licidins and defensins therefore appear to have maintained
their relevance because they also contribute to host defense
by triggering inflammatory cell recruitment and cytokine
release. This system often involves signaling mediated by
pattern recognition receptors such as TLRs or responses to
proinflammatory cytokines. The AMPs amplify defense by
calling for help.
S. epidermidis
Sebocytes
Keratinocyte
Neutrophil
T cell
Eccrine epithelial cell
Mast cell
PSMs(12)
hBDs 1 to 4(1)
Cathelicidin(2)
RNase7(3)
Psoriasin(4)
Lactoferrin(5)
Lysozyme(6)
hBDs 1 to 3(22)
Histone-H4(23)
Psoriasin(24)
Cathelicidin(25)
Granulysin(21)
Perforin(21)
SLPI(7)
Elafin(8)
α-MSH(9)
Catestatin(10)
Calprotectin(11)
α-Defensins(14)
Cathelicidin(15)
Lactoferrin(16)
Elastase(17)
Cathelicidin(18)
Dermcidin(19)
hBDs 1 to 2(20)
Cathelicidin(13)
Figure 1. The layered antimicrobial peptides of human skin. A representative partial list of antimicrobial peptides (AMPs) produced by skin-residing cells
is shown. The composition, location, timing of expression, and posttranslational processing of AMPs in the skin are all important variables that enable
them to serve a wide range of functions in defense of the skin. These functions are not only limited to action as a natural antibiotic shield, but also include the
capacity to trigger cell recruitment, growth, and differentiation. hBD, human b-defensin; a-MSH, a-melanocyte- stimulating hormone; PSM, phenol-soluble
modulin; RNase, ribonucleotidase; SLPI, secretory leukocyte peptidase inhibitor. Numbers in parentheses indicate references. (1), (Ganz et al., 1985; Harder et al.,
2001; Johnston et al., 2011); (2), (Frohm et al., 1997); (3), (Harder and Schroder, 2002); (4), (Glaser et al., 2005); (5), (Cumberbatch et al., 2000); (6), (Marchini et al.,
2002); (7), (Wingens et al., 1998); (8), (Meyer-Hoffert et al., 2003); (9), (Schauer et al., 1994; Cutuli et al., 2000); (10), (Radek et al., 2008); (11), (Abtin et al.,
2010); (12), (Cogen et al., 2010b); (13), (Di Nardo et al., 2003); (14), (Ganz, 2003); (15), (Agerberth et al., 1995; Cowland et al., 1995); (16), (Caccavo et al., 2002);
(17), (Belaaouaj et al., 2000); (18), (Murakami et al., 2004); (19), (Schittek et al., 2001); (20), (Ali et al., 2001; Oono et al., 2006); (21), (Stenger et al., 1998);
(22), (Chronnell et al., 2001; Nagy et al., 2006; Nakatsuji et al., 2010); (23), (Lee et al., 2009b); (24), (Glaser et al., 2005); (25), (Lee et al., 2008).
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AMPS AND THE PATHOPHYSIOLOGY OF HUMAN
DISEASE
As a result of the inherent association of AMPs with
inflammation, recent evidence indicates that abnormal
production of AMPs affects the pathogenesis of diseases such
as psoriasis, rosacea, and atopic dermatitis (Yamasaki and
Gallo, 2008). These observations have two important
consequences. First, they have further demonstrated the
relevance of these evolutionarily ancient genes to human
health. Second, the role of some AMPs in human disease
appears to depend more on the actions of these peptides
beyond those as an antibiotic. It is in this context that the
alternative terms such as ‘‘host defense peptide’’ or ‘‘alar-
min’’ are most appropriate.
Cathelicidins and hBDs were well known to be strongly
induced in psoriatic lesions in comparison with normal skin,
and this degree of induction mimicked expression expected
when normal skin was injured. However, the induction of
some AMPs such as cathelicidin and hBD-2 and -3 was found
to be lower in atopic dermatitis lesions than expected, despite
the presence of skin inflammation (Ong et al., 2002; Lande
et al., 2007; Hata et al., 2010; Mallbris et al., 2010). In
contrast, RNase7 and psoriasin are induced in atopic
dermatitis lesional skin, and in this case AMP induction is
appropriately upregulated by barrier disruption (Harder et al.,
2010). The defective expression of some AMPs in atopic
dermatitis has been linked to a higher propensity to
Staphylococcus aureus colonization, which is known to have
important roles in the exacerbation of the infection and is
correlated with its extent and severity of atopic lesions (Miller
et al., 2005). Thus, in this situation, a lack of the
antimicrobial function of the AMP may lead to disease.
An informative contrast to the observations in atopic
dermatitis can be made in analysis of the diseases rosacea
and psoriasis. Our group showed that an excess of
cathelicidin in the form of LL-37 exists in rosacea, and this
drives inflammation and abnormal blood vessel growth by
mechanisms of cell activation not related to antimicrobial
action (Yamasaki et al., 2007). High amounts of LL-37 appear
to result from the abnormal function of innate immune
pattern recognition by TLRs, and proteases that process
hCAP18 (Bensch et al., 1995; Jugeau et al., 2005; Yamasaki
et al., 2007, 2010). In psoriasis and systemic lupus
erythematosus, the excess presence of LL-37 enables
recognition of self-nucleic acids by both plasmacytoid
dendritic cells (Lande et al., 2007, 2011) and keratinocytes
(Morizane et al., 2011). Thus, under these conditions, AMPs
may be exacerbating inflammation and contributing to
disease by permitting autoinflammatory signaling. Expression
of AMPs is also associated with viral infectious diseases such
as mollusca contagiosm (Meyer-Hoffert et al., 2010),
condyloma acuminatum, and verruca vulgaris (Conner
et al., 2002), as well as autoimmune diseases such as
cutaneous lupus erythematosus (Kreuter et al., 2011).
MULTIFUNCTIONAL ROLES OF AMPS
As introduced by the proceeding discussion of AMPs in
human diseases, these molecules have several important
physiological and immunomodulatory functions. Some a-
and b-defensins are chemotactic for T lymphocytes, mono-
cytes, and immature dendritic cells, and can induce cytokine
production by monocytes and epithelial cells (Yang et al.,
2004). hBD-2 activates immature dendritic cells through
TLR4-dependent mechanisms, inducing a robust T helper
type 1 response (Biragyn et al., 2002). Cathelicidin triggers
inflammatory cell recruitment and cytokine release through
various mechanisms. LL-37 is a potent chemoattractant for
mast cells, monocytes, T lymphocytes, and neutrophils
through activating formyl peptide receptor–like 1 (FPRL1)
(De et al., 2000; Niyonsaba et al., 2002). The complex of
LL-37 with self-DNA or self-RNA released from dead cells
activates dendritic cells by triggering TLR9 or TLR7/8,
respectively, leasing productions of proinflammatory cyto-
kines and type-1 interferons (Lande et al., 2007, 2011;
Ganguly et al., 2009). These immunomodulatory properties
of AMPs can contribute to host defense against infections by
attracting and activating various immune cells, as well as by
their direct antimicrobial activity.
LL-37 contributes to cutaneous wound healing by stimu-
lating re-epithelialization (Heilborn et al., 2003). LL-37 also
induces neovascularization, which is mediated by FPRL1
signaling in endothelial cells, and the cathelicidin-mediated
angiogenesis is important for cutaneous wound neovascular-
ization (Koczulla et al., 2003). Furthermore, LL-37 induces
proliferation and migration by human endothelial cells
(Ramos et al., 2011). In fact, accumulation of cathelicidin
has been observed in epidermal wound and blister fluid
(Gallo et al., 1994; Frohm et al., 1996; Dorschner et al.,
2001).
THE AMPS OF OUR MICROBIOME
A surprising recent revelation is that the AMPs that directly
contribute to our skin innate immune defense are made not
only by our own cells, but also in prokaryotic organisms that
inhabit our epidermis. Our group has proposed that the
unique peptides phenol-soluble modulin (PSM)g and PSMd
produced by Staphylococcus epidermidis could be beneficial
to the host, and thus serve as additional AMPs on normal skin
surface (Cogen et al., 2010b). Although we know today from
16S sequencing approaches that the microbiome of human
skin is diverse (Grice et al., 2009), S. epidermidis was of high
interest because it is the predominant bacteria that can be
cultured from healthy human skin, and thus known to thrive
on the epidermis (Kloos and Musselwhite, 1975). PSMs
caused membrane leakage and membrane perturbation in
bacteria, as well as classic AMPs such as LL-37 and hBDs,
suggesting that these peptides function in a similar mechan-
istic manner as that of innate cutaneous AMPs. These
peptides selectively exhibited bactericidal activity against
skin pathogens, such as S. aureus, Group A Streptococcus,
and Escherichia coli, whereas they are not active against S.
epidermidis. Moreover, inoculating PSMs on the mouse skin
surface reduced the survival of Group A Streptococcus but
not S. epidermidis. This selective activity is likely to be an
important part of a normal microbial defense strategy against
colonization. In addition, PSMs enhance the capacity of
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bacterial killing activity by human neutrophils by inducing
their neutrophil extracellular traps (Cogen et al., 2010a).
These lines of discovery are only at the very early stages, and
considering the diversity of the human microbiome it is likely
that many other microbial AMPs that benefit our immune
defense will be discovered.
TARGETING AMPS FOR THERAPY
The important pleiotropic actions of AMPs, the many
examples of relevance in animal models, and their associa-
tions with human disorders all point toward this class of
molecules as a new target for therapy. In cases where
increasing AMP expression would be beneficial, such as
when attempting to treat or prevent infectious disease, a
simple therapy has shown promise. Vitamin D, long
suspected of having health benefits in infectious diseases
such as influenza and tuberculosis, has been shown to be a
potent stimulus of AMPs (Beard et al., 2011). Experiments
with cultured cells have shown that 1-25-dihydroxyvitamin
D3 enhances the expression of cathelicidin and hBD-2 by
normal human keratinocytes, resulting in an enhanced
antimicrobial function against S. aureus in vitro (Wang
et al., 2004; Schauber et al., 2008). Pilot studies have
attempted to compensate for the defective expression of
AMPs in the skin of patients suffering from atopic dermatitis
by administering vitamin D (Hata et al., 2008). Analysis of
killing of Mycobacterium tuberculosis by monocytes has
shown improvement with vitamin D (Liu et al., 2006).
However, most clinical trials have not shown a conclusive
association between vitamin D and infections in humans. It is
possible that this lack of an ability to observe an association
reflects the influence of other variables not yet understood. In
psoriasis patients, decreased expression of hBD-2 and hBD-3
were observed in lesional skin following topical administra-
tion with calcipotriol, a vitamin D analog, despite increased
expression of cathelicidin (Peric et al., 2009). The suppres-
sion of AMP expression was accompanied by decreased
expression of IL-17 and IL-8 that have important roles in
causing psoriatic inflammation. Thus, ameliorating AMP
expression is also a novel therapeutic approach for the
treatment of skin diseases with disturbed AMP expression
such as psoriasis, rosacea, or atopic dermatitis.
CONCLUSIONS
AMPs have been known for some time, but their discovery in
the skin and associations with disease are a relatively recent
advance that has opened a new chapter in immunology.
AMPs mediate the host innate immune defense through
various modes of action. A variety of factors influence AMP
expression and function. For example, a recent study from
our group demonstrated that a small molecule of o10 kDa
secreted from S. epidermidis, the predominant commensal
in healthy human skin, increased expression of hBDs in
murine skin and human keratinocytes through activation
of TLR2 signaling (Lai et al., 2010). Similarly, co-cultivation
of differentiated human primary keratinocytes with live
S. epidermidis, but not heat-inactivated bacteria, enhanced
production of hBD-2, hBD-3, and RNase7. In addition,
keratinocytes preincubated with S. epidermidis-conditioned
media strongly enhanced AMP production induced by
S. aureus, suggesting that S. epidermidis sensitizes human
keratinocytes toward pathogenic bacteria and amplifies the
innate immune response (Wanke et al., 2011). These results
suggest that the recognition of Staphylococcal molecules by
TLR2 may be involved in the steady-state production of AMPs
in keratinocytes and enhances resistance to infection by
bacterial, fungal, and viral pathogens. Thus, the correlation
between AMP expression and commensal microbiota
may be very important to maintaining skin homeostasis.
Imbalanced skin microflora would alter AMP expression in
the skin, which is critical in the pathogenesis of psoriasis,
rosacea, and atopic dermatitis. Indeed, many lines of
evidence suggest a role for the imbalanced cutaneous
microflora with pathogenicity of these disorders (Gallo and
Nakatsuji, 2011). Understanding and control of AMPs is an
exciting new part of the immunological revolution taking
place today.
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